enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Up 472.4% in April

enGene Holdings Inc. (NASDAQ:ENGN) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 72,700 shares, an increase of 472.4% from the March 31st total of 12,700 shares. Based on an average trading volume of 51,000 shares, the short-interest ratio is presently 1.4 days. Approximately 1.0% of the shares of the stock are sold short.

enGene Price Performance

NASDAQ:ENGN traded up $0.78 during midday trading on Friday, reaching $15.50. 113,417 shares of the company traded hands, compared to its average volume of 36,859. enGene has a twelve month low of $6.69 and a twelve month high of $43.00. The firm has a fifty day moving average of $16.20.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wells Fargo & Company assumed coverage on enGene in a research report on Monday, April 22nd. They issued an “overweight” rating and a $30.00 target price for the company. UBS Group assumed coverage on enGene in a research report on Thursday, March 28th. They issued a “buy” rating and a $37.00 target price for the company. SVB Leerink began coverage on enGene in a research report on Tuesday, February 20th. They issued an “outperform” rating and a $31.00 target price for the company. Guggenheim began coverage on enGene in a research report on Monday, April 15th. They set a “buy” rating and a $34.00 price objective for the company. Finally, Morgan Stanley began coverage on enGene in a research report on Friday, March 8th. They set an “overweight” rating and a $40.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $34.40.

Insider Activity at enGene

In other news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $15.00, for a total value of $717,810.00. Following the transaction, the insider now directly owns 3,036,153 shares of the company’s stock, valued at approximately $45,542,295. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Institutional Trading of enGene

Hedge funds and other institutional investors have recently modified their holdings of the company. Vivo Capital LLC acquired a new position in enGene during the fourth quarter valued at $6,264,000. Omega Fund Management LLC acquired a new position in enGene during the fourth quarter valued at $10,441,000. BVF Inc. IL acquired a new position in enGene during the fourth quarter valued at $20,777,000. Finally, Fcpm Iii Services B.V. acquired a new position in enGene during the fourth quarter valued at $80,097,000. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.